Media Teleconference: FDA Approves Alli(TM) (Orlistat 60 mg Capsules) Over-the-Counter

PITTSBURGH, Feb. 8 /PRNewswire/ --

  WHAT:    Today, the U.S. Food and Drug Administration (FDA) approved the
           weight-loss product orlistat 60 mg capsules for over-the-counter
           (OTC) use in the United States.  Marketed under the brand name
           alli(TM), this is the only FDA-approved weight-loss product soon
           to be available without a prescription and the first clinically-
           proven OTC product to be combined with a comprehensive support
           program. It is for use by overweight adults in conjunction with a
           reduced-calorie, low-fat diet.

           Please join us for a teleconference, where you will learn more
           about alli, a truly unique approach to weight loss that combines
           a safe and effective product with an innovative, personalized
           support program.   There will also be a question and answer
           session.

  WHO:     George Quesnelle, President, North America, GlaxoSmithKline
            Consumer Healthcare
           Steve Burton, Vice President, Weight Control Division,
            GlaxoSmithKline Consumer Healthcare
           Dr. Vidhu Bansal, Pharm. D, Director of Medical Affairs,
            GlaxoSmithKline Consumer Healthcare
           Caroline Apovian, MD, Director of the Center for Nutrition and
            Weight Management, Boston Medical Center

           One-on-one interviews are available upon request

  WHY:     Consumers spend billions of dollars each year on fad diets,
           unproven weight-loss miracle pills and potentially unsafe
           supplements that may not work. Approximately 65 percent of U.S.
           adults are overweight or obese, according to the National
           Institutes of Health. Overweight and obesity are associated with
           an increased risk of developing hypertension, type 2 diabetes and
           heart disease.

  WHEN:    Thursday, February 8, 2007
           10:30 a.m. - 11:30 a.m. ET

  DIAL-IN: Please use the following dial-in information to participate:
           Dial-in #: (800) 374-2482
           Conference ID #:  8026958[For International Participants,
           Dial: (706) 679-5684]

Dr. Apovian has provided medical expertise and advice throughout the development of the alli program and has received compensation for her time to do so.